ArticleBMC endocrine disorders2026
Umbilical cord asprosin and subfatin levels in relation to neonatal metabolic outcomes in gestational diabetes mellitus: a cross-sectional study.
Article in BMC endocrine disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundGestational diabetes mellitus (GDM) is a common pregnancy complication that may influence the intrauterine metabolic environment and neonatal glucose regulation. Novel adipokines such as asprosin and subfatin have been implicated in glucose homeostasis. This study aimed to evaluate umbilical cord blood levels of asprosin and subfatin in pregnancies complicated by GDM and to examine their associations with neonatal clinical and metabolic outcomes.
methodsThis cross-sectional study included 40 women with GDM, 40 healthy pregnant women, and their newborns who delivered at Balıkesir University Faculty of Medicine Hospital between August 2025 and October 2025. Maternal demographic characteristics, 75-g oral glucose tolerance test results, HbA1c levels and GDM treatment modality were recorded. Neonatal outcomes included Apgar scores, birth weight, early postnatal blood glucose levels, weight at one month and feeding mode. Umbilical cord blood asprosin and subfatin concentrations were measured using ELISA.
resultsMothers with GDM were older and had higher fasting glucose, 1- and 2-hour OGTT glucose levels, HbA1c and body mass index compared with controls (all p < 0.01). Infants born to mothers with GDM had higher birth weight (p = 0.007) and greater weight at one month (p = 0.01), while neonatal blood glucose levels were significantly lower during early postnatal follow-up (p < 0.001). In unadjusted analyses, umbilical cord asprosin (23.15 ± 10.21 vs. 35.63 ± 26.97 ng/mL, p = 0.01) and subfatin levels (2.85 ± 1.45 vs. 4.17 ± 3.11 ng/mL, p = 0.03) were lower in the GDM group. However, these differences were no longer statistically significant after multivariable adjustment (MANCOVA) for maternal age, body mass index, fetal sex and GDM treatment modality. In contrast, early neonatal blood glucose levels remained significantly lower in the GDM group after multivariable adjustment.
conclusionsPregnancies complicated by GDM are associated with differences in neonatal growth and glucose regulation, while alterations in umbilical cord adipokine levels appear to be influenced by maternal and fetal characteristics rather than representing independent effects of GDM. These findings suggest that cord blood adipokines reflect the intrauterine metabolic environment but may have limited value as independent neonatal biomarkers. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.